Local treatment of malignant brain tumors using implantable chemotherapeutic polymers

Research output: Contribution to journalArticle

Abstract

Malignant gliomas are among the most devastating human cancers. The infiltrating nature of these malignancies makes complete surgical resection nearly impossible. Conventional therapy for malignant gliomas consists primarily of surgical debulking followed by radiation therapy and possibly chemotherapy. The major factor limiting intracranial therapeutic levels of systemically administered chemotherapeutics is the physiologic barriers of the brain. This has led to the development of novel methods of drug delivery such as implantable polymers containing chemotherapeutic agents. Several phase III clinical trials show that implantation of carmustine-containing biodegradable polymers prolongs survival in patients with both recurrent and newly diagnosed malignant gliomas. In this article, we summarize these trials and discuss ongoing clinical trials involving implantable chemotherapy-containing polymers in the treatment of patients with malignant gliomas.

Original languageEnglish (US)
Pages (from-to)721-728
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number5
StatePublished - Sep 2005

Fingerprint

Brain Neoplasms
Glioma
Polymers
Drug Therapy
Carmustine
Phase III Clinical Trials
Therapeutics
Neoplasms
Radiotherapy
Clinical Trials
Survival
Brain
Pharmaceutical Preparations

Keywords

  • Brain tumor
  • Carmustine
  • Chemotherapy
  • Drug delivery
  • Gliadel®
  • Glioblastoma
  • Glioma
  • Polymer

ASJC Scopus subject areas

  • Oncology

Cite this

@article{343ed4757be64958a6f9935dee00764e,
title = "Local treatment of malignant brain tumors using implantable chemotherapeutic polymers",
abstract = "Malignant gliomas are among the most devastating human cancers. The infiltrating nature of these malignancies makes complete surgical resection nearly impossible. Conventional therapy for malignant gliomas consists primarily of surgical debulking followed by radiation therapy and possibly chemotherapy. The major factor limiting intracranial therapeutic levels of systemically administered chemotherapeutics is the physiologic barriers of the brain. This has led to the development of novel methods of drug delivery such as implantable polymers containing chemotherapeutic agents. Several phase III clinical trials show that implantation of carmustine-containing biodegradable polymers prolongs survival in patients with both recurrent and newly diagnosed malignant gliomas. In this article, we summarize these trials and discuss ongoing clinical trials involving implantable chemotherapy-containing polymers in the treatment of patients with malignant gliomas.",
keywords = "Brain tumor, Carmustine, Chemotherapy, Drug delivery, Gliadel{\circledR}, Glioblastoma, Glioma, Polymer",
author = "Gallia, {Gary L} and Steven Brem and Henry Brem",
year = "2005",
month = "9",
language = "English (US)",
volume = "3",
pages = "721--728",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Local treatment of malignant brain tumors using implantable chemotherapeutic polymers

AU - Gallia, Gary L

AU - Brem, Steven

AU - Brem, Henry

PY - 2005/9

Y1 - 2005/9

N2 - Malignant gliomas are among the most devastating human cancers. The infiltrating nature of these malignancies makes complete surgical resection nearly impossible. Conventional therapy for malignant gliomas consists primarily of surgical debulking followed by radiation therapy and possibly chemotherapy. The major factor limiting intracranial therapeutic levels of systemically administered chemotherapeutics is the physiologic barriers of the brain. This has led to the development of novel methods of drug delivery such as implantable polymers containing chemotherapeutic agents. Several phase III clinical trials show that implantation of carmustine-containing biodegradable polymers prolongs survival in patients with both recurrent and newly diagnosed malignant gliomas. In this article, we summarize these trials and discuss ongoing clinical trials involving implantable chemotherapy-containing polymers in the treatment of patients with malignant gliomas.

AB - Malignant gliomas are among the most devastating human cancers. The infiltrating nature of these malignancies makes complete surgical resection nearly impossible. Conventional therapy for malignant gliomas consists primarily of surgical debulking followed by radiation therapy and possibly chemotherapy. The major factor limiting intracranial therapeutic levels of systemically administered chemotherapeutics is the physiologic barriers of the brain. This has led to the development of novel methods of drug delivery such as implantable polymers containing chemotherapeutic agents. Several phase III clinical trials show that implantation of carmustine-containing biodegradable polymers prolongs survival in patients with both recurrent and newly diagnosed malignant gliomas. In this article, we summarize these trials and discuss ongoing clinical trials involving implantable chemotherapy-containing polymers in the treatment of patients with malignant gliomas.

KW - Brain tumor

KW - Carmustine

KW - Chemotherapy

KW - Drug delivery

KW - Gliadel®

KW - Glioblastoma

KW - Glioma

KW - Polymer

UR - http://www.scopus.com/inward/record.url?scp=33644670748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644670748&partnerID=8YFLogxK

M3 - Article

C2 - 16194460

AN - SCOPUS:33644670748

VL - 3

SP - 721

EP - 728

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 5

ER -